drug
Bortezomib Pfizer
Marketedupdated 3mo agoby Hospira Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for multiple myeloma and mantle cell lymphoma and 36 investigational indications.
all catalysts(1)
Trials studying Bortezomib Pfizer
- phase3Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
- phase3MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- phase3A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- phase3A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
- phase2A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- phase3A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- phase1A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- phase2A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 3, 2032
~6.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (7)
- Sep 23, 2042method-of-use (U-3633)US 11679119
- Sep 23, 2042method-of-use (U-3633)US 11679119
- Sep 23, 2042method-of-use (U-3633)US 11752164
- Sep 23, 2042method-of-use (U-3633)US 11752164
- Sep 23, 2042formulationUS 12005069
- Sep 23, 2042formulationUS 12005069
- Nov 3, 2032formulationUS 8962572
News(1)
- Dr Chari on Frontline Combinations and Transplant Approaches in Multiple MyelomaAjai Chari, MD, discusses frontline treatment and transplant considerations in multiple myeloma.onclive · 3mo ago
Data sources
last refreshed 15m ago
Found something off?
comments(0)
5-min edit window · permanent after that